“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Mark Stevenson, M.B.A.
Mark Stevenson is an experienced life sciences and diagnostics business leader with over 30 years’ experience commercializing innovations globally.
Mark served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, a company with over $40B in sales and a world leader in serving science through, leading its life science solutions, analytical instruments, specialty diagnostics and laboratory products businesses. He joined Thermo Fisher as Executive Vice President and President of Life Sciences Solutions through the acquisition of Life Technologies. He has also previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation.
He currently serves on the board of Ingersoll Rand Inc. (NYSE: IR), The Binding Site and the Personalized Medicine Coalition.
Mark holds an M.B.A. from Henley Management School in the U.K., a degree in chemistry from Reading University, U.K.
our leadership team
our board of directors
Director, Social & Behavioral Sciences, Community Engagement
Operation Warp Speed
Professor, Department of Gastrointestical Medical Oncology
Chair Department of Investigational Cancer Therapeutics
Chief Quality Officer
Board member, Kaiser Foundation